Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by a hemolytic reaction. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.

Abstract: The present invention provides an antisense oligonucleotide that is formed of 15-22 nucleotides and that is complementary to a nucleic acid including at least 15 consecutive bases in a specific target region of a base sequence of SEQ ID NO: 471, or a pharmaceutically acceptable salt thereof, or hydrates of those.

Abstract: The present invention provides an antisense oligonucleotide that is formed of 15-22 nucleotides and that is complementary to a nucleic acid including at least 15 consecutive bases in a specific target region of a base sequence of SEQ ID NO: 471, or a pharmaceutically acceptable salt thereof, or hydrates of those.

Abstract: The present inventors have discovered that a peptide derived from HMGB1 can be used as a therapeutic and/or preventive agent for fatty liver, nonalcoholic steatohepatitis, and various symptoms accompanied by the fatty liver. On the basis of this discovery, the present application provides a use of the peptide derived from HMGB1 which is different from conventional uses.

Abstract: A magnetic field generating device 1 comprises: an iron core 2; a pair of superconducting coils 3; and one or a pair of vacuum heat-insulation containers 4, wherein the iron core includes: a yoke 21; and a pair of split iron core portions 22 that are formed separately from the yoke, are located inside the yoke, and face each other with a work space therebetween, each of the pair of superconducting coils is wound around a different one of the pair of split iron core portions in a circumferential direction about an axis that is parallel to a direction in which the pair of split iron core portions face each other, a pair of split iron core coil assemblies 5 are stored in the one or pair of vacuum heat-insulation containers, and the yoke is located outside the one or pair of vacuum heat-insulation containers.

Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.

Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.

Abstract: An antisense nucleic acid targeting intron 6 of TDP-43 mRNA, and including a nucleotide sequence complementary to a sequence consisting of 10 or more consecutive bases in a target sequence, wherein the target sequence is the 96th to 330th or 400th to 530th positions of a nucleotide sequence represented by SEQ ID NO:1.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: The present invention provides a method of assisting a determination of whether a subject is susceptible to infection by norovirus or whether a subject is susceptible to post-infection worsening, wherein this method contains a step of measuring the concentration of IgG antibody that is present in a sample originating from within the oral cavity of the subject.

Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.

Abstract: A method for analyzing a cause of prolonging coagulation time of a blood specimen includes: adding a calcium solution to a first sample resulting from a first waiting time from mixing of a blood specimen from a subject and a measurement reagent for an activated partial thromboplastin time; obtaining a first coagulation time and/or a first parameter regarding a differential of a coagulation waveform, for the first sample; adding the calcium solution to a second sample resulting from a second waiting time, which is longer than the first waiting time, from mixing of the blood specimen from the subject and the measurement reagent; obtaining a second coagulation time and/or a second parameter regarding a differential of a coagulation waveform, for the second sample; and obtaining information regarding a cause of prolonging a coagulation time, on the basis of the first and second coagulation time and/or the first and second parameter.

Abstract: A method for preparing a compact of resin compound comprising the following steps (a) to (c): (a) a preparation step of mounting a sheet-shaped or block-shaped compact of resin compound including a resin composition, which contains a filler having magnetic anisotropy and is solidified by curing or by being advanced to a B-stage, on a transportation unit which is movable in the horizontal direction, and covering at least a top surface of the compact of resin compound with a cover material; (b) a step of applying a magnetic field to the compact of resin compound obtained in the step (a) with a bulk superconductor magnet having a central magnetic flux density of 1 T or more; and (c) a step of moving the compact of resin compound in the horizontal direction and scanning it while applying vibrations to the compact of resin compound mounted on a region of a central part of the bulk superconductor magnet under application of a magnetic field.

Abstract: Provided is a method for manufacturing a sheet for use in a tongue plaque cleaner, capable of reliably cutting loops of thread members provided at a given density, and forming thread members each having a shape with an arc portion sufficient enough to scrape off tongue plaque, through steps that are simple, low-cost and suitable for mass production. A method for manufacturing a sheet 1 for use in a tongue plaque cleaner for scraping off tongue plaque, includes: a step of heating a sheet material having multiple looped thread members 2 protruding from one surface of the sheet material, at a temperature below the melting point of the thread members 2; and a step of forming first thread members 3, 8 and second thread members 4, 9 by cutting loops of the thread members 2 heated.

Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.

Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.

Abstract: This peptide is composed of an amino acid sequence represented by general formula (I), and has a high degree of accumulation in cancer cells or cancer tissue in a digestive system. In general formula (I), X11 is a peptide residue composed of an amino acid sequence of (a) or (b) below: (a) an amino acid sequence represented by any of SEQ ID NOs: 1 to 3, (b) an amino acid sequence including a sequence in which one or two amino acids have been deleted, substituted or added in an amino acid sequence represented by any of SEQ ID NOs: 1 to 3; Y11 is a peptide linker composed of an amino acid residue of at least 1 but not more than 10 amino acids, wherein each amino acid residue is independently a glycine residue, a proline residue, a serine residue, a cysteine residue or a lysine residue; X12 is either a peptide residue composed of an amino acid sequence of (a) or (b) above, or a retro-inverso peptide residue thereof; and n11 represents an integer of at least 1 but not more than 9.

Abstract: An object of the present invention is to provide a method for preparing ambrein, which can easily and efficiently obtain the ambrein. The object can be solved by a mutated tetraprenyl-?-curcumene cyclase wherein (1) a 4th amino acid residue of a DXDD motif, aspartic acid, is substituted with an amino acid other than aspartic acid, and (2) an amino acid adjacent to the N-terminus of a (A/S/G)RX(H/N)XXP motif is substituted with an amino acid other than tyrosine, or a 4th amino acid of the GXGX(G/A/P) motif is substituted with an amino acid other than leucine.

Abstract: A nuclear magnetic resonance apparatus (100) includes: a static magnetic field former (10) that forms a static magnetic field; an object holder (2) that holds an object in the static magnetic field; a pulse applicator (51a) that applies ?/2 pulse having the Larmor frequency of an atom to be measured to the object in the static magnetic field, and then applies a ? pulse having the Larmor frequency to the object at least a predetermined number of times (the predetermined number being two or more) at an interval of the predetermined period, the ? pulse being applied for a first time at a time point at which half the predetermined period has elapsed after applying the ?/2 pulse; and a detector (40) that detects the signal intensity of a spin echo signal generated from the object as a result of the last instance of the predetermined number of times of application of the ? pulse.

Abstract: The present invention provides a method for producing a cell culture for promoting angiogenesis or axon outgrowth, particularly for the treatment of a cerebrovascular disease, an ischemic cardiac disease or traumatic brain injury and spinal cord injury, which comprises culturing a cell population containing microglia and/or monocytes under conditions of low oxygen concentration and/or low sugar concentration to produce the culture, a cell preparation obtained by the method, and a method for treating a cerebrovascular disease, an ischemic cardiac disease or traumatic cerebrospinal neuropathy by using the cell preparation.